Powering the future of digital surgery
Avamed Synergy is
Avamed Synergy is
Avamed Synergy is anticipation prevention surgical
anticipation
of tumour onset
prevention
of tumour progression
surgical
precision
anticipation
of tumour onset
prevention
of tumour progression
surgical
precision
anticipation
of tumour onset
prevention
of tumour progression
surgical
precision
WHERE DO WE START FROM?
The real problem resides in the complexity of cancer as a disease, as there are hundreds of types of cancers and each one is generated and acts differently in each person.
Faced with this problem, Fluxus, the main project of Avamed Synergy, was born. Fluxus is destined to be the only clinical innovative environment that will be a paradigm shift in predictive oncology, developing a systematic method to predict the future state of an individual tumour.
Assisted by Artificial Intelligence (AI) and with proprietary native algorithms it provides a tumour-host interface model with multi-scale data and uncertainty quantification.
The future of diagnosis and surgery is collaborative:
human judgement + increased wisdom + digital precision
Our goal is to anticipate the dynamics of tumour growth and its classification, allowing us to eliminate potential unwanted complications in treatment and during surgery, improving results and impact on patients.
Benefits of Fluxus
For oncologists
Although Fluxus is not a diagnostic tool, it improves accuracy in tumour differentiation, which allows better prediction of tumour growth dynamics and improves treatment planning. According to our clinical trial results (non-public medical study), Fluxus reduces false negatives by 70% and helps to avoid overdoses and excessive treatment times. This technology supports personalised medicine, improves patient outcomes and reduces healthcare costs.
For surgeons
Fluxus empowers surgical planning through advanced simulation capabilities, minimising surgical errors and increasing safety. It allows surgeons to rehearse complex surgeries, reducing surgical time by up to 30% and reducing non-tumour tissue resections by 15%. This leads to fewer postoperative complications and better patient outcomes.
For patients
Fluxus provides more detailed information on disease status, possible progression and decisions for longer life expectancy, reduced radiation exposure and better recovery outcomes. Our studies estimate that in the next 10 to 15 years our technology will be able to reduce overdose and overtreatment by 80%, preventing chronic diseases.
For society
Fluxus reduces surgical costs by 12% and overall costs by 29%, through more efficient and accurate treatments. It also optimises healthcare resources by making imaging equipment, such as MRI scanners, more available for other critical needs, improving the overall delivery of healthcare services.
Benefits of Fluxus
For oncologists
Although Fluxus is not a diagnostic tool, it improves accuracy in tumour differentiation, which allows better prediction of tumour growth dynamics and improves treatment planning. According to our clinical trial results (non-public medical study), Fluxus reduces false negatives by 70% and helps to avoid overdoses and excessive treatment times. This technology supports personalised medicine, improves patient outcomes and reduces healthcare costs.
For surgeons
Fluxus empowers surgical planning through advanced simulation capabilities, minimising surgical errors and increasing safety. It allows surgeons to rehearse complex surgeries, reducing surgical time by up to 30% and reducing non-tumour tissue resections by 15%. This leads to fewer postoperative complications and better patient outcomes.
For patients
Fluxus provides more detailed information on disease status, possible progression and decisions for longer life expectancy, reduced radiation exposure and better recovery outcomes. Our studies estimate that in the next 10 to 15 years our technology will be able to reduce overdose and overtreatment by 80%, preventing chronic diseases.
For society
Fluxus reduces surgical costs by 12% and overall costs by 29%, through more efficient and accurate treatments. It also optimises healthcare resources by making imaging equipment, such as MRI scanners, more available for other critical needs, improving the overall delivery of healthcare services.
Our achievements
Our achievements
Nuestros logros
Our latest news
Avamed Synergy is participating in a business development mission to New York and Boston organized by IVACE+i
Avamed Synergy is participating in a business development mission to New York and Boston organized by IVACE+i Part of the team traveled to explore new opportunities within a large innovation ecosystem During the week of 12 to 18 October,
Avamed Synergy at Satelec 2026
Avamed Synergy stands out at Satelec 2026 with a booth that connects with young talent Avamed Synergy’s participation in the ETSIT-UPM Employment and Technology Forum has drawn a large number of students, generating significant interest in medical imaging and artificial intelligence On February 26, Avamed Synergy participated in Satelec 2026, the Employment and Technology Forum
Avamed Synergy strengthens its international presence in Boston during the Spain-United States Business Summit
Avamed Synergy strengthens its international presence in Boston during the Spain-United States Business Summit The company is taking part in the business mission organised by ICEX in the United States, connecting with key players in the biotech and
Avamed Synergy receives funding from the Valencian Regional Government
Avamed Synergy receives funding from the Valencian Regional Government to develop a new artificial intelligence project for bariatric surgery The biotechnology company Avamed Synergy has been awarded funding by the Valencian Regional Government to develop a project entitled
- WHERE WE ARE -
Distrito Digital (Alicante)
Digital District: Avenida de Atoñita Moreno, s/n- Building nº 1, 3RD floor, 03008 Alicante (Spain).
965 316 801 // 965 317 749
